ATAI - ATAI Life Sciences GAAP EPS of $0.25
2023-11-14 07:28:21 ET
More on ATAI Life Sciences
- Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies
- Psychedelic drugs market to break $7B in 2029 led by these 3 meds
- Psychedelics research amendments advance in House committee
- Seeking Alpha’s Quant Rating on ATAI Life Sciences
- Historical earnings data for ATAI Life Sciences
For further details see:
ATAI Life Sciences GAAP EPS of $0.25